$GOVX
GeoVax Labs, Inc.

2023 Q4 Form 10-Q Financial Statement

#000143774923030926 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.460M $1.650M
YoY Change -10.05% 32.07%
% of Gross Profit
Research & Development $6.234M $6.948M
YoY Change 65.59% 155.33%
% of Gross Profit
Depreciation & Amortization $22.21K $20.00K
YoY Change 57.85% 13.19%
% of Gross Profit
Operating Expenses $7.694M $8.600M
YoY Change 42.81% 116.59%
Operating Profit -$8.600M
YoY Change 116.59%
Interest Expense $101.3K $190.0K
YoY Change 2646.34%
% of Operating Profit
Other Income/Expense, Net $190.9K
YoY Change 7754.22%
Pretax Income -$7.592M -$8.410M
YoY Change 41.02% 111.94%
Income Tax
% Of Pretax Income
Net Earnings -$7.592M -$8.409M
YoY Change 41.02% 111.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$3.83 -$0.32
COMMON SHARES
Basic Shares Outstanding 26.70M 26.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.453M $12.69M
YoY Change -76.63% -63.41%
Cash & Equivalents $6.453M $12.69M
Short-Term Investments
Other Short-Term Assets $1.433M $2.110M
YoY Change 8.08% 44.5%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $7.886M $14.80M
YoY Change -72.75% -59.04%
LONG-TERM ASSETS
Property, Plant & Equipment $209.7K $213.0K
YoY Change -10.74% -14.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.188M $1.188M
YoY Change -45.37% -45.62%
Total Long-Term Assets $1.397M $1.401M
YoY Change -41.99% -42.43%
TOTAL ASSETS
Total Short-Term Assets $7.886M $14.80M
Total Long-Term Assets $1.397M $1.401M
Total Assets $9.283M $16.20M
YoY Change -70.39% -58.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.803M $4.213M
YoY Change 60.38% 290.33%
Accrued Expenses $716.9K $2.868M
YoY Change -76.1% -22.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.520M $7.082M
YoY Change -25.86% 47.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.520M $7.082M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.520M $7.080M
YoY Change -25.86% 4.28%
SHAREHOLDERS EQUITY
Retained Earnings -$104.4M -$96.77M
YoY Change 33.12% 32.54%
Common Stock $110.1M $105.9M
YoY Change 4.89% 1.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.763M $9.119M
YoY Change
Total Liabilities & Shareholders Equity $9.283M $16.20M
YoY Change -70.39% -58.0%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.592M -$8.409M
YoY Change 41.02% 111.91%
Depreciation, Depletion And Amortization $22.21K $20.00K
YoY Change 57.85% 13.19%
Cash From Operating Activities -$10.28M -$5.100M
YoY Change 45.49% 34.24%
INVESTING ACTIVITIES
Capital Expenditures $18.95K $10.00K
YoY Change -119.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$18.95K -$10.00K
YoY Change -80.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.062M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -10.28M -5.100M
Cash From Investing Activities -18.95K -10.00K
Cash From Financing Activities 4.062M 0.000
Net Change In Cash -6.234M -5.110M
YoY Change -11.75% -235.38%
FREE CASH FLOW
Cash From Operating Activities -$10.28M -$5.100M
Capital Expenditures $18.95K $10.00K
Free Cash Flow -$10.30M -$5.110M
YoY Change 45.76% 36.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6947979 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1651775 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8599754 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
190936 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8408818 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3968102 usd
us-gaap Net Income Loss
NetIncomeLoss
-18374354 usd
us-gaap Net Income Loss
NetIncomeLoss
-8637316 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26544058
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
75000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
228039 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4037916 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
22865157 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
226013 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5927620 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
17163550 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
738281 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000832489
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8599754 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13818315
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26600034 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
137500 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
227114 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8408818 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9119346 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4361704 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9229248 usd
CY2022Q1 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
24 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2427515 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11353652 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18497946 usd
CY2022Q2 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
567 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
72000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2241699 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
27872657 usd
CY2022Q3 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
7625543 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60750 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3968102 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
31781039 usd
us-gaap Net Income Loss
NetIncomeLoss
-8637316 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51956 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42213 usd
us-gaap Share Based Compensation
ShareBasedCompensation
813499 usd
us-gaap Share Based Compensation
ShareBasedCompensation
650895 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-0 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-49006 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
707084 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1251539 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-986498 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2173276 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2333791 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-645955 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3478660 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-3328656 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14895694 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11965972 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29997 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
134258 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29997 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-134258 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27727194 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7626134 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35353328 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14925691 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23253098 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11423870 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12687041 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34676968 usd
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt; font-size: 10pt;"><b>1.</b></td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Nature of Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing immunotherapies and vaccines against cancers and infectious diseases using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy for advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) Zika virus, and malaria, as well as immunotherapies for solid tumors.</p>
CY2023Q3 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1986037 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1171077 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
0 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
107876 usd
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
114167 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2113249 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325998 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
871414 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
841417 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
658461 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
606505 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212953 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234912 usd
CY2023Q3 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
1106778 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
2083276 usd
CY2023Q3 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
70000 usd
CY2022Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1187788 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2174286 usd
CY2023Q3 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2022Q4 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2023Q3 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
133665 usd
CY2022Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
550810 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
734725 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
449402 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2868390 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3000212 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
108696
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
178253
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
73385
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13384115
CY2023Q3 govx Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.77
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y9M18D
CY2023Q3 govx Prepaid Expense Value Of Stock Issued For Services During Period
PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
104167 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15402915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14346415

Files In Submission

Name View Source Status
0001437749-23-030926-index-headers.html Edgar Link pending
0001437749-23-030926-index.html Edgar Link pending
0001437749-23-030926.txt Edgar Link pending
0001437749-23-030926-xbrl.zip Edgar Link pending
ex_590328.htm Edgar Link pending
ex_590329.htm Edgar Link pending
ex_590330.htm Edgar Link pending
ex_590331.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
govx-20230930.xsd Edgar Link pending
govx20230930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
govx-20230930_cal.xml Edgar Link unprocessable
govx-20230930_def.xml Edgar Link unprocessable
govx20230930_10q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
govx-20230930_lab.xml Edgar Link unprocessable
govx-20230930_pre.xml Edgar Link unprocessable